Close Menu

Bucking the Trend

This may mess up your "merger madness" bracket (kind of like Villanova is doing for the basketball brackets): Eli Lilly is not interested in a merger with Bristol-Myers Squibb, reports the Financial Times. CEO John Lechleiter told the FT that he'd rather "work to boost his company's internal development of experimental medicines alongside selective smaller-scale deals."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.